When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Cardiomiopatia hipertrófica

Evidence last reviewed: 18 Oct 2026
Topic last updated: 01 May 2025

Summary

Definition

History and exam

Key diagnostic factors

  • história familiar de CMH
  • história de pré-síncope ou de síncope
  • sopro sistólico de ejeção
  • elevação ventricular esquerda (ictus)
  • impulso apical duplo ou dupla pulsação da carótida
  • história familiar de morte súbita
Full details

Other diagnostic factors

  • homem mais jovem (<50 anos de idade)
  • dispneia
  • angina
  • palpitações
  • pulso irregularmente irregular
  • mulher de idade mais avançada (>50 anos de idade)
  • colapso
  • quarta bulha cardíaca
Full details

Risk factors

  • história familiar de cardiomiopatia hipertrófica (CMH) ou morte súbita cardíaca
Full details

Diagnostic tests

1st tests to order

  • eletrocardiograma (ECG)
  • creatina quinase (CK)
  • testes da função hepática
  • testes de função renal
  • Fragmento N-terminal do peptídeo natriurético tipo B (NT-proPNB)
  • troponina
  • urinálise
  • radiografia torácica
  • ecocardiografia transtorácica com Doppler
Full details

Tests to consider

  • eletrocardiografia de esforço
  • monitoramento com Holter
  • teste ergométrico com cintilografia
  • ressonância nuclear magnética cardíaca (RNMC)
  • Tomografia computadorizada cardíaca (TC)
  • arteriografia coronariana por tomografia computadorizada (TC)
  • cateterismo cardíaco
  • ecocardiografia sob estresse
  • ecocardiografia por esforço
  • ecocardiografia transesofágica
  • biópsia endomiocárdica
  • análise de mutações genéticas
Full details

Treatment algorithm

ONGOING

assintomático

sintomático: obstrução da via de saída do ventrículo esquerdo com função sistólica preservada (fração de ejeção ≥50%)

sintomático: não obstrutivo com função sistólica preservada (fração de ejeção ≥50%)

sintomático: com disfunção sistólica (fração de ejeção <50%)

Contributors

Authors

Theodore Abraham, MD

Professor of Medicine and Radiology

Meyer Friedman Distinguished Professor of Medicine

Co-director, UCSF HCM Center of Excellence

University of California

San Francisco

CA

Disclosures

TA serves as a steering committee member/local investigator and his institution has received research funding for hypertrophic cardiomyopathy-related clinical trials sponsored by Bristol Myers Squibb; Cytokinetics Inc.; Tenaya Pharmaceuticals; and Imbria Pharmaceuticals.

Acknowledgements

Dr Theodore Abraham would like to gratefully acknowledge Dr Monica Mukherjee, Dr Melanie D. Everitt, and Dr Anji T. Yetman, previous contributors to this topic.

Disclosures

MM, MDE, and ATY declare that they have no competing interests.

Peer reviewers

Radhika Kuna, MD

Fellow

Division of Cardiology

University of Maryland Medical Center

Baltimore

MD

Disclosures

RK declares that she has no competing interests.

Saidi Mohiddin, BSc, MBChB

Consultant Cardiologist/Head of Unit

Heart Muscle Disease Unit

Barts and The London NHS Trust

London

UK

Disclosures

SM declares that he has no competing interests.

Peer reviewer acknowledgements

BMJ Best Practice topics are updated on a rolling basis in line with developments in evidence and guidance. The peer reviewers listed here have reviewed the content at least once during the history of the topic.

Disclosures

Peer reviewer affiliations and disclosures pertain to the time of the review.

References

Our in-house evidence and editorial teams collaborate with international expert contributors and peer reviewers to ensure that we provide access to the most clinically relevant information possible.

Key articles

Arbelo E, Protonotarios A, Gimeno JR, et al. 2023 ESC Guidelines for the management of cardiomyopathies. Eur Heart J. 2023 Oct 1;44(37):3503-626.Full text  Abstract

Writing Committee Members, Ommen SR, Ho CY, et al. 2024 AHA/ACC/AMSSM/HRS/PACES/SCMR guideline for the management of hypertrophic cardiomyopathy: a report of the American Heart Association/American College of Cardiology Joint Committee on clinical practice guidelines. J Am Coll Cardiol. 2024 Jun 11;83(23):2324-405.Full text  Abstract

Richard P, Charron P, Carrier L, et al. Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy. Circulation. 2003 May 6;107(17):2227-32. [Erratum in: Circulation. 2004 Jun 29;109(25):3258.]Full text  Abstract

O'Mahony C, Jichi F, Pavlou M, et al. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD). Eur Heart J. 2014 Aug 7;35(30):2010-20.Full text  Abstract

Pelliccia A, Sharma S, Gati S, et al. 2020 ESC guidelines on sports cardiology and exercise in patients with cardiovascular disease. Eur Heart J. 2021 Jan 1;42(1):17-96.Full text  Abstract

Reference articles

A full list of sources referenced in this topic is available to users with access to all of BMJ Best Practice.
  • Cardiomiopatia hipertrófica images
  • Differentials

    • Coração de atleta
    • Estenose subaórtica distinta
    • HVE causada por hipertensão
    More Differentials
  • Guidelines

    • 2024 AHA/ACC/AMSSM/HRS/PACES/SCMR guideline for the management of hypertrophic cardiomyopathy
    • 2023 ESC Guidelines for the management of cardiomyopathies
    More Guidelines
  • Videos

    Galope de quarta bulha cardíaca

    More videos
  • padlock-lockedLog in or subscribe to access all of BMJ Best Practice

Use of this content is subject to our disclaimer